CN114981436A - 新tlr9激动剂 - Google Patents

新tlr9激动剂 Download PDF

Info

Publication number
CN114981436A
CN114981436A CN202180010073.7A CN202180010073A CN114981436A CN 114981436 A CN114981436 A CN 114981436A CN 202180010073 A CN202180010073 A CN 202180010073A CN 114981436 A CN114981436 A CN 114981436A
Authority
CN
China
Prior art keywords
seq
oligonucleotide
modified
cells
phosphorothioate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180010073.7A
Other languages
English (en)
Chinese (zh)
Inventor
江指永二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Publication of CN114981436A publication Critical patent/CN114981436A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180010073.7A 2020-01-10 2021-01-08 新tlr9激动剂 Pending CN114981436A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-002715 2020-01-10
JP2020002715 2020-01-10
PCT/JP2021/000543 WO2021141121A1 (en) 2020-01-10 2021-01-08 Novel tlr9 agonists

Publications (1)

Publication Number Publication Date
CN114981436A true CN114981436A (zh) 2022-08-30

Family

ID=76787976

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180010073.7A Pending CN114981436A (zh) 2020-01-10 2021-01-08 新tlr9激动剂

Country Status (11)

Country Link
US (1) US12686870B2 (enExample)
EP (1) EP4087931B1 (enExample)
JP (1) JP7750525B2 (enExample)
KR (1) KR20220125218A (enExample)
CN (1) CN114981436A (enExample)
AU (1) AU2021206355B2 (enExample)
BR (1) BR112022007935A2 (enExample)
CA (1) CA3161956A1 (enExample)
IL (1) IL294621A (enExample)
MX (1) MX2022005633A (enExample)
WO (1) WO2021141121A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024153142A1 (zh) * 2023-01-19 2024-07-25 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022249092A1 (en) * 2021-04-01 2023-10-12 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
RU2400538C2 (ru) 2005-03-05 2010-09-27 Сиджен, Инк. Олигонуклеотид с двойственной специфичностью и способы, в которых он используется
WO2006095941A1 (en) 2005-03-05 2006-09-14 Seegene, Inc. Processes using dual specificity oligonucleotide and dual specificity oligonucleotide
JP5011520B2 (ja) 2005-08-12 2012-08-29 国立大学法人 長崎大学 新規ヒト形質細胞様樹状細胞株
JP2010536787A (ja) 2007-08-15 2010-12-02 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｏｌｌ様受容体モジュレータ
US20110136897A1 (en) 2008-08-14 2011-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
KR101856462B1 (ko) 2009-03-25 2018-05-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
JP6106280B2 (ja) 2012-11-29 2017-03-29 Ｓｂｉバイオテック株式会社 阻害性オリゴヌクレオチド及びその使用
CN105518153A (zh) 2013-06-20 2016-04-20 因姆内克斯普雷斯私人有限公司 生物标志物鉴定
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
EP3302501B1 (en) * 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
CA3020873A1 (en) 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
MX2019005502A (es) 2016-11-09 2020-10-01 Univ Texas Metodos y composiciones para inmunomodulacion adaptativa.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024153142A1 (zh) * 2023-01-19 2024-07-25 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用

Also Published As

Publication number Publication date
WO2021141121A1 (en) 2021-07-15
JP7750525B2 (ja) 2025-10-07
KR20220125218A (ko) 2022-09-14
CA3161956A1 (en) 2021-07-15
EP4087931A4 (en) 2024-01-24
US12686870B2 (en) 2026-07-21
AU2021206355A1 (en) 2022-07-07
MX2022005633A (es) 2022-06-14
EP4087931A1 (en) 2022-11-16
JP2023510491A (ja) 2023-03-14
US20230323368A1 (en) 2023-10-12
AU2021206355B2 (en) 2026-06-04
BR112022007935A2 (pt) 2022-07-12
EP4087931B1 (en) 2024-12-25
IL294621A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
JP6885867B2 (ja) 組合せ腫瘍免疫療法
AU2013271375B2 (en) Compositions and methods for cancer immunotherapy
JP2025084910A (ja) タンパク質抗原およびその使用
EP3666887A2 (en) Method for activating t cells for cancer treatment
CN112105383A (zh) 用于治疗hpv相关疾病的方法
CN110770345A (zh) 免疫调节多核苷酸、抗体缀合物及其使用方法
JP2019524766A (ja) 免疫応答を調節するための生体材料
CN106687122B (zh) β-葡聚糖与影响肿瘤微环境的抗癌剂的组合
WO2013113736A1 (en) Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
JP2019515900A (ja) がんを処置するためのＴｏｌｌ様レセプター９アゴニストおよび腫瘍抗原を含む粒子の腫瘍内送達
CN110229813B (zh) 具有疫苗佐剂作用和肿瘤治疗作用的寡核苷酸
US20240165263A1 (en) Targeting multiple t cell types using spherical nucleic acid vaccine architecture
KR20140014077A (ko) 교모세포종의 치료를 위한 치료 조성물
Wang et al. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics
EP4087931B1 (en) Novel tlr9 agonists
CN106893724B (zh) 具有抗原增效作用和肿瘤治疗作用的寡核苷酸
KR102908492B1 (ko) 신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물
RU2846775C1 (ru) Новые агонисты tlr9
CN101161288B (zh) 寡核苷酸增强的肿瘤细胞裂解物及其在制备治疗肿瘤的药物中的应用
Jeon Role of toll-like receptor agonists as cancer vaccine adjuvants
CN101333237B (zh) 一种具有治疗乳腺癌作用的寡核苷酸
RU2799784C2 (ru) Способы лечения заболеваний, ассоциированных с впч
Kim et al. Expression of UNC93A induced by CpG-DNA-liposome complex in mice
CN121950809A (zh) 含CpG基序的干扰PD-L1表达的抗肿瘤脱氧寡核苷酸
CN121472222A (zh) 抗肿瘤双功能单链脱氧寡核苷酸

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination